newcharttop570
HµRELdogTM
Developed through a funded R&D collaboration with UCB Pharma, HµRELdogTM, the first characterized canine primary hepatocyte-based 3D tissue culture, complements the Company’s HµRELhumanTM, HµRELratTM, and HµRELprimateTM products and enables inter-species comparative studies. Published in Toxicology and Applied Pharmacology.

more


Based on the results of a 51-compound study they performed, UCB scientists concluded that the HµRELdogTM co-culture constitutes “a promising model for chronic studies in metabolism and toxicity” that “outperforms two other widely used cellular systems and represents a novel and effective platform for predicting pharmacokinetics and toxicity profiles of drugs under development.”

dogimagesforhureldogpage

HµRELToxTM
multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
HµRELviralTM
Long-enduring infectious liver disease platform
Time-Based
Toxicity Ratios*
A new marker for hepatotoxic chronicity

TAAP
*patent pending
HµRELfluxTM
a new, patent-pending
efflux transport
assay method
DMPK
Superior intrinsic clearance
and biotransformation of
low-turnover drugs

DMD